Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Lung Cancer

Free Subscription 16.03.2026 1 AJR Am J Roentgenol 1 Am J Clin Oncol 1 Am J Ind Med 1 Am J Respir Crit Care Med 1 Am J Surg 1 Ann Oncol 8 Ann Surg Oncol 3 Ann Thorac Surg 1 Anticancer Res 1 Arch Pathol Lab Med 3 BMC Cancer 2 Br J Cancer 1 Cancer 3 Cancer Cell 6 Cancer Lett 1 Cancer Res 3 Cancer Sci 6 Chest 6 Clin Cancer Res 1 Clin Lung Cancer 3 Clin Nucl Med 1 Eur J Cardiothorac Surg 1 Eur Respir J 1 Genes Chromosomes Cancer 1 Int J Cancer 1 Int J Oncol 2 Int J Radiat Oncol Biol Phys 2 J Cancer Res Clin Oncol 1 J Natl Cancer Inst 1 J Nucl Med 4 J Surg Oncol 4 J Thorac Cardiovasc Surg 9 J Thorac Oncol 2 JAMA Oncol 2 Lancet Oncol 17 Lung Cancer 3 Mol Carcinog 1 Oncogene 1 Oncol Rep 2 Oncologist 2 PLoS Comput Biol 6 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. GRAUR A, Simon J, Westphal JA, Moscho DC, et al
   Associations of Pleural Puncture Angle and Other Factors With Major Adverse Events After Thermal Lung Tumor Ablation: A Two-Center Study.
   AJR Am J Roentgenol. 2026;226:e2533549.
   PubMed         Abstract available
   
   

   
   Am J Clin Oncol

2. YUAN H, Wang W, Wei Z, Zhang L, et al
   Enhancing the Diagnostic Performance of Early Lung Cancer by Integrating Multiplex Nucleic Acid Aptamer Detection With Conventional Tumor Markers: A Prospective Observational Study.
   Am J Clin Oncol. 2026 Mar 11. doi: 10.1097/COC.0000000000001316.
   PubMed         Abstract available
   
   

   
   Am J Ind Med

3. RINGEN K, Dement JM, Cloeren M, Almashat S, et al
   Impact of Secondary Prevention on Mortality in the Building Trades National Medical Screening Program: Effectiveness of Occupational High-Risk Management.
   Am J Ind Med. 2026;69:241-253.
   PubMed         Abstract available
   
   

   
   Am J Respir Crit Care Med

4. THIBOUTOT J, Pastis NJ, Akulian J, Silvestri GA, et al
   A Multicenter, Single-Arm, Prospective Trial Assessing the Diagnostic Yield of Electromagnetic Bronchoscopic and Transthoracic Navigation for Peripheral Pulmonary Nodules.
   Am J Respir Crit Care Med. 2023;208:837-845.
   PubMed         Abstract available
   
   

   
   Am J Surg

5. FU K, Li Y, Feng KP, Chen JW, et al
   The limited protective effect of prolonged smoking cessation on postoperative outcomes in uniportal video-assisted thoracic surgery for pulmonary nodules.
   Am J Surg. 2026;254:116847.
   PubMed         Abstract available
   
   

   
   Ann Oncol

6. FROST N, Reck M
   Reply to Letter Re: PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM).
   Ann Oncol. 2026 Mar 4:S0923-7534(26)00063-3. doi: 10.1016/j.annonc.2026.
   PubMed        
   
   

   
   Ann Surg Oncol

7. DENG HY, Daoud A, Zhou Q
   Preoperative Frailty Assessment: An Important Component of Preoperative Planning for Lung Cancer Surgery.
   Ann Surg Oncol. 2026 Mar 12. doi: 10.1245/s10434-026-19464.
   PubMed        
   
   
8. LIU Z, Zhao C, Shao W, Chen F, et al
   Myocardial Injury After Lung Cancer Surgery: Incidence, Characteristics, Risk Factors, and Prognosis: A Retrospective Cohort Study.
   Ann Surg Oncol. 2026 Mar 5. doi: 10.1245/s10434-026-19386.
   PubMed         Abstract available
   
   
9. TANE S, Maniwa Y
   ASO Author Reflections: Salvage Surgery in the Immunotherapy Era: A New Paradigm for Advanced Non-Small Cell Lung Cancer.
   Ann Surg Oncol. 2026 Mar 3. doi: 10.1245/s10434-026-19409.
   PubMed        
   
   
10. FOLKERT IW, Mehran R, Sun R, Morris VK, et al
    Hepatectomy Plus Chemotherapy or Chemotherapy Alone for Resectable Liver and Unresectable Lung Metastases from Colorectal Adenocarcinoma (LUNA): A Randomized Phase II Trial.
    Ann Surg Oncol. 2026;33:2899-2907.
    PubMed         Abstract available
    
    
11. NAKANOKO T, Kawazoe T, Hirose K, Hu Q, et al
    Prediction of Tracheobronchial Invasion in ycT3 Esophageal Cancer Using Contact Angle on Preoperative CT Images: A Multicenter Analysis.
    Ann Surg Oncol. 2026;33:3076-3083.
    PubMed         Abstract available
    
    
12. KINOSHITA F, Takada K, Wakasu S, Saito S, et al
    Granzyme B (GZMB)-Positive Tumor-Infiltrating Lymphocytes in Lung Adenocarcinoma: Significance as a Prognostic Factor and Association with Immunosuppressive Proteins.
    Ann Surg Oncol. 2023;30:7579-7589.
    PubMed         Abstract available
    
    
13. YANG Z, Li X, Bai J, Li D, et al
    Prognostic Factors for Survival of Stage IB Non-small Cell Lung Cancer Patients: A 10-Year Follow-Up Retrospective Study.
    Ann Surg Oncol. 2023;30:7481-7491.
    PubMed         Abstract available
    
    
14. TIAN JY, Hao XY, Cao FY, Liu JJ, et al
    Preoperative Frailty Assessment Predicts Postoperative Mortality, Delirium and Pneumonia in Elderly Lung Cancer Patients: A Retrospective Cohort Study.
    Ann Surg Oncol. 2023;30:7442-7451.
    PubMed         Abstract available
    
    

    
    Ann Thorac Surg

15. WANG S, Zhou Y, Hu S, Bian D, et al
    Neoadjuvant chemoimmunotherapy followed by surgery or radiotherapy for stage IIIA-B non-small cell lung cancer with bulky N2 disease.
    Ann Thorac Surg. 2026 Mar 5:S0003-4975(26)00199.
    PubMed         Abstract available
    
    
16. ROSENSTEIN AL, Potter AL, Senthil P, Raman V, et al
    The Role of Salvage Resection After Definitive Radiation Therapy for Non-small Cell Lung Cancer.
    Ann Thorac Surg. 2023;116:997-1003.
    PubMed         Abstract available
    
    
17. ZHOU N, Niu J, Nelson D, Feldman HA, et al
    Surgical Approach and Persistent Opioid Use in Medicare Patients Undergoing Lung Cancer Resection.
    Ann Thorac Surg. 2023;116:1020-1027.
    PubMed         Abstract available
    
    

    
    Anticancer Res

18. HAQUE EF, Tanino R, Okimoto T, Hotta T, et al
    Concurrent Pemetrexed With EGFR-TKI Slows the Accumulation of De Novo Mutations During In Vitro Exposure.
    Anticancer Res. 2026;46:1323-1335.
    PubMed         Abstract available
    
    

    
    Arch Pathol Lab Med

19. KIM MY, Kim H, Sung JA, Koh J, et al
    Whole Mitochondrial Genome Analysis in Non-Small Cell Lung Carcinoma Reveals Unique Tumor-Specific Somatic Mutations.
    Arch Pathol Lab Med. 2023;147:1268-1277.
    PubMed         Abstract available
    
    

    
    BMC Cancer

20. KAPADI A, Howard G, Merchant Z, Crosbie PAJ, et al
    Improving access and uptake of lung cancer screening with a focus on health inequity: the views of professionals involved in the UK NHS lung cancer screening programme.
    BMC Cancer. 2026 Mar 9. doi: 10.1186/s12885-026-15766.
    PubMed        
    
    
21. DAI P, Zhou H, Lian Q, Zhang Z, et al
    Risk factors for pulmonary metastases in osteosarcoma: a systematic review and meta-analysis.
    BMC Cancer. 2026 Mar 5. doi: 10.1186/s12885-026-15802.
    PubMed        
    
    
22. DA SILVA SARDENBERG RA, de Campos CAL, Porto BC, da Cruz JAS, et al
    Lung cancer treatment pathways in the largest private health insurance in Brazil: a real-world data study.
    BMC Cancer. 2026 Mar 4. doi: 10.1186/s12885-026-15702.
    PubMed        
    
    

    
    Br J Cancer

23. DONG Z, Xie W, Zhang N, Guo Y, et al
    Myc-mediated epigenetic silencing of ACAP3 promotes lung adenocarcinoma proliferation via regulating EGFR dynamics.
    Br J Cancer. 2026;134:860-873.
    PubMed         Abstract available
    
    
24. WANG M, Fan J, Mu B, Zeng Y, et al
    HDAC5 stabilization by tubeimoside I suppresses cervical cancer metastasis via inhibiting H3K27ac/KPNA2 axis.
    Br J Cancer. 2026 Jan 8. doi: 10.1038/s41416-025-03328.
    PubMed         Abstract available
    
    

    
    Cancer

25. GANDARA DR, Gumus M, Kilickap S, Sezer A, et al
    Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy.
    Cancer. 2026;132:e70339.
    PubMed         Abstract available
    
    

    
    Cancer Cell

26. DUAN J, Sun Y, Wang Q, Xing L, et al
    HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial.
    Cancer Cell. 2026 Mar 5:S1535-6108(26)00104-2. doi: 10.1016/j.ccell.2026.
    PubMed         Abstract available
    
    
27. CAMPISI M, Osaki T, Dryg I, Stornante C, et al
    Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer.
    Cancer Cell. 2026 Mar 5:S1535-6108(26)00106-6. doi: 10.1016/j.ccell.2026.
    PubMed         Abstract available
    
    
28. MATEUS-TIQUE J, Lakshmi A, Singh B, Iyer R, et al
    Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth.
    Cancer Cell. 2026;44:534-550.
    PubMed         Abstract available
    
    

    
    Cancer Lett

29. YAN JS, Wang YZ, Zhao SY, Na FJ, et al
    Immunotherapy for extensive-stage small cell lung cancer: current status, challenges and future strategies.
    Cancer Lett. 2026;645:218382.
    PubMed         Abstract available
    
    
30. LIANG S, Wang Q, Zhang M, Song X, et al
    A tumor-derived mitochondrial tsRNA drives vascular invasion of lung adenocarcinoma by promoting ribosomal assembly in endothelial cells.
    Cancer Lett. 2026;644:218324.
    PubMed         Abstract available
    
    
31. ARBEL R, Rokach L, Razi T, Tadmor T, et al
    Validation of "SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade" in an independent cohort of 4,407 patients.
    Cancer Lett. 2026;643:218319.
    PubMed         Abstract available
    
    
32. YANG J, Yu H, Zhong C, Xu L, et al
    Liver cancer-derived exosomal PTK6 induces the secretion of pulmonary CHI3L1 to facilitate lung metastatic niche formation.
    Cancer Lett. 2026;643:218312.
    PubMed         Abstract available
    
    
33. WANG H, Tian X, Zhu W, Wang Y, et al
    ZBTB20 promotes malignancy and stemness in lung squamous cell carcinoma through the transcriptional repression of KCTD1 and activation of Hedgehog signaling.
    Cancer Lett. 2026;643:218301.
    PubMed         Abstract available
    
    
34. LIU D, Liu B, Yang R, Song J, et al
    Targeting Galectin-9 to overcome immunosuppression and potentiate ATR inhibitor therapy.
    Cancer Lett. 2026;643:218283.
    PubMed         Abstract available
    
    

    
    Cancer Res

35. BRADY MR, Matulionis N, Christofk HR, Garon EB, et al
    Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma.
    Cancer Res. 2026;86:1166-1179.
    PubMed         Abstract available
    
    

    
    Cancer Sci

36. TSURUDA T, Kodama M, Nakayama KI
    Small Cell Lung Cancer Establishes a Metabolic Autocrine Mechanism Through Active Extracellular ATP Transport.
    Cancer Sci. 2026 Mar 2. doi: 10.1111/cas.70350.
    PubMed         Abstract available
    
    
37. ONO Y, Otsu H, Masuda T, Kosai K, et al
    PSMD12 Overexpression Promotes Lung Adenocarcinoma Progression via Ubiquitin-Proteasome Pathway Dysregulation.
    Cancer Sci. 2026;117:644-656.
    PubMed         Abstract available
    
    
38. KUDO H, Morishima T, Fujii M, Nagayasu M, et al
    Prognostic impact of the presence or absence of prior cancer in patients with cancer using cure models: A population-based study.
    Cancer Sci. 2023;114:4041-4051.
    PubMed         Abstract available
    
    

    
    Chest

39. SHAIKH FA, Panesar H, Curran T, Nemeth ZH, et al
    Standardizing Exposure Metrics and Imaging Interpretation in Cannabis-Tobacco Co-Use and Lung Cancer.
    Chest. 2026;169:e120-e121.
    PubMed        
    
    
40. GRIFFIN W, Craughwell M, Sheehy B, Fabre A, et al
    A 77-Year-Old Woman With a Slowly Enlarging Pulmonary Nodule.
    Chest. 2026;169:e109-e114.
    PubMed         Abstract available
    
    
41. PAPAVASSILIOU KA, Papavassiliou AG
    Integrating Tumor Biology into Anatomy: The Future of Lung Cancer Staging.
    Chest. 2026;169:602-604.
    PubMed        
    
    
42. YOUNG RP, Scott RJ
    Preserved Ratio Impaired Spirometry: A Treatable Trait Identified by Spirometry When Elevated Risk of Lung Cancer and Cardiovascular Death Coexist.
    Chest. 2026;169:592-595.
    PubMed        
    
    
43. KAYE JT, Kathuria H
    Rethinking Smoking: Cannabis, Tobacco, and Lung Cancer.
    Chest. 2026;169:586-588.
    PubMed        
    
    
44. JUSTEAU G, Greillier L, Vinas F, Falchero L, et al
    Association of sleep-related hypoxemia with survival in patients with non-small cell lung cancer - the NEOSAS-GFPC study group.
    Chest. 2026 Mar 9:S0012-3692(26)00279-5. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

45. SIERRA-RODERO B, Gil-Gonzalez A, Molina-Alejandre M, Nadal E, et al
    Decoding B Cell Signatures of Complete Pathological Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2026 Mar 10. doi: 10.1158/1078-0432.CCR-25-3315.
    PubMed         Abstract available
    
    
46. GRAY JE, Laktionov K, Kim SW, Kato T, et al
    Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2026 Mar 9. doi: 10.1158/1078-0432.CCR-25-3431.
    PubMed         Abstract available
    
    
47. YU HA, Tang KH, Markovets AA, Hartmaier R, et al
    Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study.
    Clin Cancer Res. 2026 Mar 6. doi: 10.1158/1078-0432.CCR-25-4540.
    PubMed         Abstract available
    
    
48. WU X, Sun K, Zhang J, Hou S, et al
    Locus-specific human endogenous retrovirus ERVK18 expression indicates an inflamed microenvironment and favorable immunotherapy outcome in small cell lung cancer.
    Clin Cancer Res. 2026 Mar 5. doi: 10.1158/1078-0432.CCR-25-3302.
    PubMed         Abstract available
    
    
49. ZHOU X, Zhou L, Yao Z, Huang M, et al
    Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small Cell Lung Cancer Patients.
    Clin Cancer Res. 2023;29:4098-4108.
    PubMed         Abstract available
    
    
50. GRAY JE, Ahn MJ, Oxnard GR, Shepherd FA, et al
    Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.
    Clin Cancer Res. 2023;29:3340-3351.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

51. WILDMAN VL, Qiu RLJ, Mandawat A, Luca K, et al
    Cardiac Substructure Dose Response after Lung Cancer Radiotherapy.
    Clin Lung Cancer. 2026 Feb 6:S1525-7304(26)00027.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

52. BEKKHOUCHA A, Agrigoroaie L, Deandreis D, Guyon D, et al
    Lung Metastases from Meningioma Diagnosed on Whole Body 68Ga-DOTATOC PET/CT and Successfully Targeted With 177Lu-DOTATATE.
    Clin Nucl Med. 2026;51:335-337.
    PubMed         Abstract available
    
    
53. WEISSENSEE A, Bregenzer CM, Viscione M, Mingels C, et al
    Imaging of Small Lung Nodules on Modern SAFOV and LAFOV PET in Combination With Data-driven Motion Correction: Implications for Current Practice.
    Clin Nucl Med. 2025 Dec 26. doi: 10.1097/RLU.0000000000006278.
    PubMed         Abstract available
    
    
54. DASAR M, Eroglu Elden H, Akbulut A, Ertunc O, et al
    Incidental Finding of PSMA-avid Pulmonary Sclerosing Pneumocytoma on 68Ga PSMA PET-CT.
    Clin Nucl Med. 2025 Jul 21. doi: 10.1097/RLU.0000000000006069.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

55. HA G, Coe L, Jindani R, Quintero-Rodriguez JH, et al
    Does robotic surgery offer advantages over thoracoscopic surgery for patients undergoing wedge resection for non-small cell lung cancer?
    Eur J Cardiothorac Surg. 2026 Feb 27:ezag109. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Eur Respir J

56. KUO YW, Chen YL, Chen YH, Chang YL, et al
    Shear-wave elastography-guided transthoracic biopsy for lung lesions: a randomised controlled trial.
    Eur Respir J. 2026;67:2402370.
    PubMed         Abstract available
    
    

    
    Genes Chromosomes Cancer

57. DWIRANTI A, Nabila GZ, Zalyanti TA, Irdianto SA, et al
    Extrachromosomal DNA Detection and Ultrastructural Profiling in Lung and Colorectal Cancer Models.
    Genes Chromosomes Cancer. 2026;65:e70115.
    PubMed         Abstract available
    
    

    
    Int J Cancer

58. HUANG P, Song J, Liu J, Li Y, et al
    Clinicopathological and genomic features of early-onset non-small cell lung cancer across age and ethnicity.
    Int J Cancer. 2026 Mar 7. doi: 10.1002/ijc.70425.
    PubMed         Abstract available
    
    

    
    Int J Oncol

59. WEI Q, Huang C, Zhang Y, Zeng H, et al
    IL?6: A key player in the EGFR?TKI?resistant tumor microenvironment and its therapeutic implications (Review).
    Int J Oncol. 2026;68:47.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

60. ITO S, Nakajima Y, Fujita Y, Capaldi DPI, et al
    Comparison of Computed Tomography Ventilation Imaging and Hyperpolarized (3)He Magnetic Resonance Imaging in Patients with Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2026 Mar 7:S0360-3016(26)00480.
    PubMed         Abstract available
    
    
61. BUCKNELL NW, Hardcastle N, Woon B, Selbie L, et al
    The HI-FIVE Trial: A Prospective Trial Using 4-Dimensional (68)Ga Ventilation-Perfusion Positron Emission Tomography-Computed Tomography for Functional Lung Avoidance in Locally Advanced Non-small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2023;117:887-892.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

62. ZHU Y, Yang Y, Liu Y, Qian H, et al
    A novel tetraspanin-related gene signature for predicting prognosis and immune invasion status of lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:13631-13643.
    PubMed         Abstract available
    
    
63. ZHU X, Yu B, Shen Y, Zhao Y, et al
    Screening biomarkers for predicting the efficacy of immunotherapy in patients with PD-L1 overexpression.
    J Cancer Res Clin Oncol. 2023;149:12965-12976.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

64. LIM H, Byun J, Ripley RT, Choi J, et al
    Methylation signatures distinguish non small cell lung cancer subtypes and associated with survival in smokers with lung squamous cell carcinoma.
    J Natl Cancer Inst. 2026 Mar 10:djag067. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Nucl Med

65. KESSLER L, Schwaning F, Metzenmacher M, Pabst KM, et al
    Prognostic Value of Fibroblast Activation Protein-Directed PET Imaging in Pleural Mesothelioma.
    J Nucl Med. 2026 Jan 8:jnumed.125.270906. doi: 10.2967/jnumed.125.270906.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

66. SABARI J, Stiles BM
    Best Practices for the Multidisciplinary Care of Patients With Early-Stage Driver-Mutated Non-Small Cell Lung Cancer.
    J Surg Oncol. 2026 Mar 11. doi: 10.1002/jso.70214.
    PubMed         Abstract available
    
    
67. 
    RETRACTION: Comparison of a Risk Calculator With Frailty Indices in Patients Undergoing Lung Cancer Resection.
    J Surg Oncol. 2026 Mar 9. doi: 10.1002/jso.70232.
    PubMed         Abstract available
    
    
68. VAN DORP M, Unal S, Gooijer S, Dickhoff C, et al
    Salvage surgery for local recurrences after stereotactic ablative radiotherapy of colorectal pulmonary metastases.
    J Surg Oncol. 2023;128:1114-1120.
    PubMed         Abstract available
    
    
69. MURAOKA Y, Yotsukura M, Yoshida Y, Nakagawa K, et al
    Dynamics of recurrence after curative resection of nonsmall cell lung cancer.
    J Surg Oncol. 2023;128:1205-1212.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

70. ITO A, Kang SW, Jang HJ, Shim JS, et al
    Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2026 Mar 4:S0022-5223(26)00187.
    PubMed         Abstract available
    
    
71. ZHU S, He C, Zhang X, Zhao Y, et al
    Clinic-radiologic predictors of pathological characteristics in pure ground-glass nodules: Development and validation of a predictive nomogram.
    J Thorac Cardiovasc Surg. 2026;171:742-753.
    PubMed         Abstract available
    
    
72. KHALIL HA, Shi W, Mazzola E, Lee DN, et al
    Analysis of recurrence in lung adenocarcinoma with spread through air spaces.
    J Thorac Cardiovasc Surg. 2023;166:1317-1328.
    PubMed         Abstract available
    
    
73. WHITHAM T, Wima K, Harnett B, Kues JR, et al
    Lung cancer screening utilization rate varies based on patient, provider, and hospital factors.
    J Thorac Cardiovasc Surg. 2023;166:1331-1339.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

74. TRIPHURIDET N, Ou SI
    The "Inflammatory-Mutagenic" Landscape of Systemic Sclerosis (SSc)-Associated Lung Cancer: Distinct Genomics and Therapeutic Implications.
    J Thorac Oncol. 2026;21:103536.
    PubMed        
    
    
75. PONCE S, Ruiz-Torres M, Falcon A, Cote GM, et al
    Combination of Lurbinectedin plus Irinotecan: Preclinical and Early Clinical Results in Relapsed Small Cell Lung Cancer Patients.
    J Thorac Oncol. 2026 Mar 4:103654. doi: 10.1016/j.jtho.2026.103654.
    PubMed         Abstract available
    
    
76. AGRAFIOTIS AC, Rami-Porta R, Altorki N, Van Schil PE, et al
    Journal of Thoracic Oncology 20th Anniversary Series Surgery.
    J Thorac Oncol. 2026;21:103530.
    PubMed         Abstract available
    
    
77. RECK M, Patel JD, Gray JE, Reguart N, et al
    First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study.
    J Thorac Oncol. 2026;21:103509.
    PubMed         Abstract available
    
    
78. PENG LS, Cui Q, Zhang C, Lin JT, et al
    Neoadjuvant Immunochemotherapy in Resectable NSCLC With SMARCA4 Alterations.
    J Thorac Oncol. 2026;21:103506.
    PubMed         Abstract available
    
    
79. CHEN MF, Lee JJ, Choudhury NJ, Hui AB, et al
    Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases.
    J Thorac Oncol. 2026;21:103505.
    PubMed         Abstract available
    
    
80. ODINTSOV I, Hammer MM, Ricciuti B, Pecci F, et al
    The Genomic Landscape of NSCLC in Systemic Sclerosis Reveals Frequent TP53 Mutations and a Paucity of Actionable Oncogenes.
    J Thorac Oncol. 2026;21:103501.
    PubMed         Abstract available
    
    
81. ZHANG X, Wen Y, Wu F, Jiang Y, et al
    GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma.
    J Thorac Oncol. 2026;21:103494.
    PubMed         Abstract available
    
    
82. EVANS WK, Tammemagi MC, Walker MJ, Cameron E, et al
    Integrating Smoking Cessation Into Low-Dose Computed Tomography Lung Cancer Screening: Results of the Ontario, Canada Pilot.
    J Thorac Oncol. 2023;18:1323-1333.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

83. CHORADIA N, Desai A, Naqash AR
    Insurance Barriers to Next-Generation Sequencing Testing in Lung Cancer-When Policy Delays Care.
    JAMA Oncol. 2026 Mar 12. doi: 10.1001/jamaoncol.2025.6459.
    PubMed        
    
    
84. LEI J, Zhao J, Gong L, Ni Y, et al
    Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial.
    JAMA Oncol. 2023;9:1348-1355.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

85. LEONHARDT CS, Adham M, Bazarbashi S, Ben-Aharon I, et al
    The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer.
    Lancet Oncol. 2026;27:e141-e149.
    PubMed         Abstract available
    
    
86. KIM Y, Bates JE, Yoon HI, Grassberger C, et al
    Cardiac radiosensitivity in the era of thoracic chemoradiotherapy and immunotherapy: a scoping review.
    Lancet Oncol. 2026;27:e130-e140.
    PubMed         Abstract available
    
    

    
    Lung Cancer

87. ASMARA OD, Lancaster HL, Field JK, Davies MPA, et al
    Volume and location of screen-detected lung nodules associated with lung cancer within two-year follow-up: Post hoc analysis from the UK Lung Cancer Screening (UKLS) trial.
    Lung Cancer. 2026;215:109352.
    PubMed         Abstract available
    
    
88. BROSSEAU S, Etienne H, Peoc'h K, Langlais A, et al
    Club cell secretory protein (CCSP) serum concentration is a prognostic factor after surgical resection of localized non-small cell lung cancer in patients in the IFCT-0302 trial.
    Lung Cancer. 2026;215:109345.
    PubMed         Abstract available
    
    
89. YIU CH, Clarke SJ, Lu CY
    Real-world outcomes of pembrolizumab-chemotherapy combination in metastatic non-small cell lung cancer by age and sex: A national population-based study.
    Lung Cancer. 2026;214:109340.
    PubMed         Abstract available
    
    
90. CITARELLA F, Venanzi FM, Di Giovanni G, Takada K, et al
    Family history enrichment in Non-Small cell Lung Cancer: A cross-sectional - prospective study to inform referral for germline testing.
    Lung Cancer. 2026;214:109346.
    PubMed         Abstract available
    
    
91. GOUTAM S, Raghavan AA, Alday H, Meyers DE, et al
    Outcomes and toxicities of immune checkpoint inhibitors in patients with lung cancer and pre-existing autoimmune disease.
    Lung Cancer. 2026;214:109347.
    PubMed         Abstract available
    
    
92. TODA M, Takada K, Nomura K, Kosai K, et al
    Lack of impact of antibiotics and proton pump inhibitors on the efficacy of preoperative chemoimmunotherapy in locally advanced non-small cell lung cancer: A multicenter retrospective study.
    Lung Cancer. 2026;214:109344.
    PubMed         Abstract available
    
    
93. LI F, Qi L, Wusiman D, Chen J, et al
    Comparative clinical utility of the 2024 Fleischner Society updated glossary versus traditional classifications for pulmonary subsolid nodules.
    Lung Cancer. 2026;214:109306.
    PubMed         Abstract available
    
    
94. YIN LX, Huang ZJ, Wu L, Wang F, et al
    Prognostic impact and treatment options for EGFR-mutant non-small cell lung cancer with concurrent EGFR amplification.
    Lung Cancer. 2026;214:109339.
    PubMed         Abstract available
    
    
95. FERNANDEZ-BUSSY S, Yu Lee-Mateus A, Murillo-Torres RM, Gutierrez-Gallegos P, et al
    Bronchoscopic pulsed-electric field ablation for carcinoid tumor: robotic-assisted and non-robotic approach.
    Lung Cancer. 2026;214:109333.
    PubMed         Abstract available
    
    
96. ZHANG Q, Sun J, Yang Y, Xu B, et al
    Survival analysis and prognostic factors in advanced NSCLC harboring EGFR PACC mutations: A multicenter retrospective study.
    Lung Cancer. 2026;214:109341.
    PubMed         Abstract available
    
    
97. POMPILI C, Jaques L, Callister MEJ, Franks KN, et al
    Patient-reported EORTC QLQ C-30 global health status decline predicts survival after video-assisted thoracoscopic (VATS) lung resection and stereotactic ablative radiotherapy (SABR): A 5 year follow-up from the Lilac study.
    Lung Cancer. 2026;214:109335.
    PubMed         Abstract available
    
    
98. SUN Z, Liu T, Xu J, Wang B, et al
    RET Fusion-Positive Lung Adenocarcinoma: Partner-Specific Clinicopathological Characteristics, Co-Mutation Profiles, and Implications for Targeted and Immunotherapy.
    Lung Cancer. 2026;214:109314.
    PubMed         Abstract available
    
    
99. RECK M, Waller C, Sadjadian P, Kambartel K, et al
    Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung - An AIO phase Ib/II trial.
    Lung Cancer. 2026;214:109318.
    PubMed         Abstract available
    
    
100. HAYASHI H, Cho BC, Kim YJ, Lee SH, et al
     Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis.
     Lung Cancer. 2026;214:109305.
     PubMed         Abstract available
     
     
101. WANG J, Wang X, Li Y, Huang C, et al
     Safety evaluation of tarlatamab: A pharmacovigilance study based on the FAERS database.
     Lung Cancer. 2026;214:108801.
     PubMed         Abstract available
     
     
102. LI H, Chen Y, Wei L, Wu P, et al
     HDAC1-modified lamin A/C drives nuclear deformation in RB1-deficient lung adenocarcinoma.
     Lung Cancer. 2026;214:109301.
     PubMed         Abstract available
     
     
103. STOCKHAMMER P, Baumeister H, Ploenes T, Bonella F, et al
     Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma.
     Lung Cancer. 2023;185:107360.
     PubMed         Abstract available
     
     

     
     Mol Carcinog

104. CASTILLO-SANCHEZ R, Ordonez-Moreno A, Torres-Alamilla P, Cortes-Reynosa P, et al
     PI3K Activity Mediates the Epithelial to Mesenchymal Transition Process in MCF10A Cells and Tumor Growth and Metastasis in a Murine Model of Breast Cancer.
     Mol Carcinog. 2026;65:434-447.
     PubMed         Abstract available
     
     
105. QIAO R, Zhu Q, Di F, Liu C, et al
     Hypomethylation of DYRK4 in peripheral blood is associated with increased lung cancer risk.
     Mol Carcinog. 2023;62:1745-1754.
     PubMed         Abstract available
     
     
106. WANG B, Shen XY, Pan LY, Li Z, et al
     The HDAC2-MTA3 interaction induces nonsmall cell lung cancer cell migration and invasion by targeting c-Myc and cyclin D1.
     Mol Carcinog. 2023;62:1630-1644.
     PubMed         Abstract available
     
     

     
     Oncogene

107. LIU X, Tian F, Cui J, Gong L, et al
     CUL4B functions as a tumor suppressor in KRAS-driven lung tumors by inhibiting the recruitment of myeloid-derived suppressor cells.
     Oncogene. 2023;42:3113-3126.
     PubMed         Abstract available
     
     

     
     Oncol Rep

108. HU P, Li A
     ACSBG1?driven lipid reprogramming unveiled: A fatty acid metabolism?associated prognostic model for lung adenocarcinoma.
     Oncol Rep. 2026;55:82.
     PubMed         Abstract available
     
     

     
     Oncologist

109. LIU M, Hu Q, Zhang X, Wu Z, et al
     Triangulating Associations Between Fruit Intake and Lung Cancer Risk: Evidence from GBD Estimates, Mendelian Randomization, and Real-World Validation.
     Oncologist. 2026 Feb 27:oyag069. doi: 10.1093.
     PubMed         Abstract available
     
     
110. MALINOU JN, Fan J, Cheng J, Gong Y, et al
     An FDA analysis of the association of tumor growth rate, overall survival, and progression-free survival in patients with metastatic non-small cell lung cancer.
     Oncologist. 2026;31:oyag009.
     PubMed         Abstract available
     
     

     
     PLoS Comput Biol

111. LI R, Hu DM, Liu YL, Zhao W, et al
     Multi-omics and network pharmacology identify IGFBP1 as an m6A-Epigenetic target of pueraria in NSCLC therapy.
     PLoS Comput Biol. 2026;22:e1014050.
     PubMed         Abstract available
     
     
112. VU T, Seal S, Ghosh T, Ahmadian M, et al
     FunSpace: A functional and spatial analytic approach to cell imaging data using entropy measures.
     PLoS Comput Biol. 2023;19:e1011490.
     PubMed         Abstract available
     
     

     
     PLoS One

113. ZHAO W, Yi L, Wu G, Gao Z, et al
     C1RL-AS1/microRNA-424-5p/adrenoceptor beta2 axis: A novel regulatory mechanism in lung adenocarcinoma associated with immune infiltration and prognosis.
     PLoS One. 2026;21:e0343805.
     PubMed         Abstract available
     
     
114. JI C, Yao Y, Gui M
     Analysis and prediction of the burden of lung cancer attributable to diet low in fruits in China and the global from 1990 to 2021.
     PLoS One. 2026;21:e0342584.
     PubMed         Abstract available
     
     
115. KIM EY, Kim JS, Jin KN, Cho YJ, et al
     Accuracy and reproducibility of tumor size measurement using a deep-learning-based CDSS in resected lung cancer.
     PLoS One. 2026;21:e0344445.
     PubMed         Abstract available
     
     
116. MYERS SP, Tsung C, Chen JC, Gokun Y, et al
     Factors correlated with financial hardship among cancer patients during the COVID-19 pandemic.
     PLoS One. 2026;21:e0342984.
     PubMed         Abstract available
     
     
117. BAEISSA HM, Bakhsh T, Shakoori AM, Sindi G, et al
     Correction: Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins.
     PLoS One. 2026;21:e0344592.
     PubMed         Abstract available
     
     
118. GODFREY CM, Leech AA, McGann KC, Zhu J, et al
     Cost-effectiveness analysis of artificial intelligence-assisted risk stratification of indeterminate pulmonary nodules.
     PLoS One. 2026;21:e0343492.
     PubMed         Abstract available
     
     

     
     Proc Natl Acad Sci U S A

119. NIKOLIC J, Ackermann J, Marin I, Taheraly S, et al
     Adhesion forces between macrophages and cancer cells promote early tumor development.
     Proc Natl Acad Sci U S A. 2026;123:e2514484123.
     PubMed         Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum